Verastem enters into research collaboration with Eisai

theflyonthewall.com

Verastem announced a research collaboration with Eisai for the next-generation of small molecule Wnt inhibitors. VS-507 is a proprietary formulation of salinomycin and will be the starting point for the development of proprietary analogs in the collaboration with Eisai. The resulting compounds will be tested in Verastem’s Wnt signaling and cancer stem cell assays to evaluate their selective activity. Verastem will own the analogs that are generated in the 12-month collaboration. Eisai will be eligible to receive royalties on commercial sales of identified products.

View Comments (0)